Actively Recruiting
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Led by University of Pennsylvania · Updated on 2026-04-22
14
Participants Needed
1
Research Sites
158 weeks
Total Duration
On this page
Sponsors
U
University of Pennsylvania
Lead Sponsor
I
Incyte Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
CONDITIONS
Official Title
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, age 18-80
- Documented disease history consistent with diagnostic criteria for iMCD
- Refractory, relapsed, or unable to tolerate anti-IL-6 or anti-IL-6 receptor therapy
- Evidence of active disease with at least two of specified symptoms or laboratory abnormalities
- Able to take oral medication in tablet form
- Able to provide informed consent before study activities
You will not qualify if you...
- Pregnant or nursing females
- Females of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study and for 12 weeks after
- Received systemic therapy for iMCD other than corticosteroids or anti-IL-6 therapy within 14 days of enrollment
- Corticosteroid use must be stable or tapering and started more than 28 days before enrollment
- Previous use of ruxolitinib for iMCD
- Uncontrolled or exclusionary infections, including active tuberculosis, hepatitis B or C
- ECOG performance status higher than 3
- Severe kidney impairment or certain low blood counts
- Liver enzyme levels more than three times the normal upper limit
- Low albumin or platelet counts as defined
- Pulmonary involvement with dyspnea or low oxygen levels
- Very high fasting cholesterol or triglyceride levels
- Rheumatologic diseases that mimic or exclude iMCD
- Prior malignancy except certain treated skin and cervical cancers or cancers with life expectancy over 5 years
- Documented HIV, HHV-8 infection, or severe combined immunodeficiency
- Major cardiac events within 6 months before enrollment
- Participation in other iMCD or immunomodulatory clinical trials
- Allergy or sensitivity to ruxolitinib or its components
- Serious medical or psychiatric illness that interferes with study participation
- Psychiatric disorders compromising informed consent
- Any other condition the investigator determines makes participation inappropriate
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
B
Bridget Austin, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here